BattellePharma Signs Product Development Agreement With Corus Pharma.Business Editors & Health/Medical Writers BIOWIRE2K COLUMBUS, Ohio--(BW HealthWire)--June 11, 2002 BattellePharma, Inc. today announced it has signed a development and licensing agreement with Abaris Pharma Inc. a subsidiary of Corus Pharma to develop an inhaled version of a novel compound for asthma. Abaris Pharma will use BattellePharma's proprietary Mystic(TM) inhalation technology for the delivery of its lidocaine lidocaine /li·do·caine/ (li´do-kan) an anesthetic with sedative, analgesic, and cardiac depressant properties, applied topically in the form of the base or hydrochloride salt as a local anesthetic; also used in the latter form as a drug. In addition to receiving a fully reimbursed development contract, BattellePharma will receive an upfront payment, program milestone payments and royalties on product revenues. "Corus Pharma chose BattellePharma's Mystic technology for the delivery of our asthma compound because it offers improved drug delivery efficiency and very consistent dosing. We believe that these properties will ensure the best results for our product in both clinical trials and ultimately in the asthma market," said A. Bruce Montgomery Bruce Montgomery might refer to:
Corus Pharma's program shows significant clinical data demonstrating the efficacy of lidocaine in various asthmatic patient types. The data from the studies showed that when using aerosolized Adj. 1. aerosolized - in the form of ultramicroscopic solid or liquid particles dispersed or suspended in air or gas aerosolised gaseous - existing as or having characteristics of a gas; "steam is water is the gaseous state" lidocaine to treat asthma, there is high therapeutic index with throat numbing as the only major side effect. By using BattellePharma's Mystic delivery system to administer lidocaine, Corus Pharma intends to eliminate or minimize the throat anesthetic effect of lidocaine. BattellePharma's Mystic electrohydrodynamic inhalation technology addresses the limitations other inhalers experience, including inconsistent dosing and poor delivery efficiencies. Existing devices, such as metered dose and dry powder inhalers, often require patients to produce specific coordinated and difficult breathing patterns, which limit the effectiveness of the devices. In a clinical trial, the Mystic device achieved 80 percent delivery of the drug to the lung versus 20 percent in a competitive marketed inhaler inhaler /in·hal·er/ (in-hal´er) 1. an apparatus for administering vapor or volatilized medications by inhalation. 2. ventilator (2). in·hal·er n. . Mystic exceeds the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. guidelines, while providing maximum safety and efficacy for the patient. The technology can be used for pulmonary delivery of small molecules, proteins/peptides and DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. . "The Mystic technology was developed by BattellePharma to more effectively deliver medicine directly where it is needed in the lung," said Dennis B. Cearlock, CEO of BattellePharma. "We are pleased that Corus chose to partner with us for its asthma therapy. We believe that our devices that offer accurate, reliable dosing for a broad range of novel formulations across all patient populations will set the standard for pulmonary drug delivery." About Corus Pharma Corus Pharma is a pharmaceutical company committed to developing and obtaining regulatory approvals for infectious diseases infectious diseases: see communicable diseases. and respiratory-related products for improved health and superior quality of life. About BattellePharma BattellePharma is a pre-public specialty pharmaceutical company leveraging science and technology to design more effective medicines. The company has a growing portfolio of nine products in development, with several in early clinical trials. The products are based on three proprietary platforms: Mystic(TM) inhalation technology, novel formulation technologies, and inhaled anticancer therapy. The company develops products by combining these platforms with novel or generic compounds to create therapies to treat respiratory and systemic diseases and lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. . BattellePharma has partnerships with numerous pharmaceutical corporations, including Abbott Laboratories, GlaxoSmithKline, Pfizer Inc., Viasys Healthcare, and ViroPharma, Inc. and is a subsidiary of Battelle Memorial Institute The Battelle Memorial Institute is a private not-for-profit applied science and technology development company headquartered in Columbus, Ohio. The institute opened in 1929 but traces its origins to the 1923 will of Ohio industrialist Gordon Battelle which provided for its , the world's largest independent and private research and development organization. For more information on BattellePharma, reference the company's website at www.battellepharma.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion